Ernexa Therapeutics Inc. Fair Value Adjustment of Warrants
Ernexa Therapeutics Inc. (ERNA) reported Fair Value Adjustment of Warrants of -$1.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-06
- Ernexa Therapeutics Inc. fair value adjustment of warrants for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Ernexa Therapeutics Inc. fair value adjustment of warrants for the quarter ending 2025-09-30 was $0.00.
- Ernexa Therapeutics Inc. fair value adjustment of warrants for the quarter ending 2025-06-30 was $0.00.
- Ernexa Therapeutics Inc. fair value adjustment of warrants for the quarter ending 2025-03-31 was -$1.00K, a 101.43% decline year-over-year.
- Ernexa Therapeutics Inc. fair value adjustment of warrants for fiscal 2025 was -$1.00K.
- Ernexa Therapeutics Inc. fair value adjustment of warrants for fiscal 2024 was -$414.00K.
- Ernexa Therapeutics Inc. fair value adjustment of warrants for fiscal 2023 was -$215.00K.
- Ernexa Therapeutics Inc. fair value adjustment of warrants for fiscal 2022 was -$10.79M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $0.00 derived: sum of 2 quarters · filed 2026-03-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | -$1.00K 10-K · filed 2026-03-13 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | -$1.00K 10-Q · filed 2025-11-07 | $482.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.00K 10-Q · filed 2026-08-06 | $482.00K derived: sum of 3 quarters · filed 2026-08-06 | -$349.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$1.00K 10-Q · filed 2026-05-11 | $482.00K derived: sum of 2 quarters · filed 2026-05-11 | -$349.00K derived: sum of 3 quarters · filed 2026-05-11 | -$485.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $483.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$348.00K derived: sum of 2 quarters · filed 2026-03-13 | -$484.00K derived: sum of 3 quarters · filed 2026-03-13 | -$414.00K 10-K · filed 2026-03-13 |
| 2024-09-30 | -$831.00K 10-Q · filed 2025-11-07 | -$967.00K derived: sum of 2 quarters · filed 2025-11-07 | -$897.00K 10-Q · filed 2025-11-07 | -$946.00K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$136.00K 10-Q · filed 2025-08-13 | -$66.00K 10-Q · filed 2025-08-13 | -$115.00K derived: sum of 3 quarters · filed 2025-08-13 | -$135.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $70.00K 10-Q · filed 2025-05-07 | $21.00K derived: sum of 2 quarters · filed 2025-05-07 | $1.00K derived: sum of 3 quarters · filed 2025-05-07 | -$190.00K derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$69.00K derived: sum of 2 quarters · filed 2025-03-12 | -$260.00K derived: sum of 3 quarters · filed 2025-03-12 | -$215.00K 10-K · filed 2025-03-12 |
| 2023-09-30 | -$20.00K 10-Q · filed 2024-11-12 | -$211.00K derived: sum of 2 quarters · filed 2024-11-12 | -$166.00K 10-Q · filed 2024-11-12 | -$468.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$191.00K 10-Q · filed 2024-08-13 | -$146.00K 10-Q · filed 2024-08-13 | -$448.00K derived: sum of 3 quarters · filed 2024-08-13 | -$1.47M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $45.00K 10-Q · filed 2024-05-14 | -$257.00K derived: sum of 2 quarters · filed 2024-05-14 | -$1.28M derived: sum of 3 quarters · filed 2024-05-14 | |
| 2022-12-31 | -$302.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$1.32M derived: sum of 2 quarters · filed 2024-03-14 | -$10.79M 10-K · filed 2024-03-14 | |
| 2022-09-30 | -$1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$10.49M 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | -$9.47M 10-Q · filed 2023-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |